Abstract
Patients affected by Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) show specific epigenetic and gene expression signatures of the disease. However, it is unknown whether these signatures include abnormal levels of the human angiotensin-converting enzymes, ACE and ACE2, the latter being the main receptor described for the host-cell invasion by SARS-CoV-2. To investigate that, we first re-analyzed available case-control epigenome-wide association studies based on DNA methylation data, and case-control gene expression studies based on microarray data. From these published studies, we found an association between ME/CFS and 4 potentially hypomethylated probes located in the ACE locus. We also found another disease association with one hypomethylated probe located in the transcription start site of ACE2. The same disease associations were obtained for women but not for men after performing sex-specific analyses. In contrast, a meta-analysis of gene expression levels could not provide evidence for a differentially expression of ACE and ACE2 in affected patients when compared to healthy controls. In line with this negative finding, the analysis of a new data set on the gene expression of ACE and ACE2 in peripheral blood mononuclear cells did not find any differences between a female cohort of 37 patients and 34 age-matched healthy controls. Future studies should be conducted to extend this investigation to other potential receptors used by SARS-CoV-2. These studies will help researchers and clinicians to improve the understanding of the health risk imposed by this virus when infecting patients affected by this debilitating disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JM and AF were fully funded by Fundação para a Ciência e Tecnologia, Portugal (ref.grant: SFRH/BD/149758/2019 and SFRH/BD/147629/2019, respectively). NS and CC were partially funded by Fundação para a Ciência e a Tecnologia, Portugal (ref. grant: UIDB/00006/2020). LN and EML acknowledge the funding from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH -Award Number: R01AI103629), and from the ME Association (Award number: PF8947) for their studies on ME/CFS. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funding agencies did not have any role in the designing, data collection, data analysis, interpretation or writing-up the present manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol of the German ME/CFS cohort study was approved by the Ethics Committee of Charité-Universitätsmedizin Berlin in accordance with the 1964 Declaration of Helsinki and its later amendments (reference number EA2/067/20). All patients and healthy controls recruited from staff gave written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declarations of interest: none
We revised the first version of the manuscript after receiving the reviewers' comments. Briefly, we have extended our analysis of the DNA methylation data to the transcription start sites of ACE/ACE2. We have now identified 5 disease associations in contrast with our negative findings from the first version (revised Figure 1C). We have also moved our discussion about the Genome-Wide Association studies to the Discussion and revised the title of the manuscript accordingly. Finally, we have now performed a sex-specific analysis of DNA methylation data. We identified the same disease associations for women as in the overall analysis (new Figure 1D). We did not find any disease association for men (new Figure 1E).
Data Availability
Data sets from epigenetic-wide and gene expression studies are publicly available at the NCBI GEO data repository. The data set from the German cohort is available from Prof Carmen Scheibenbogen upon request.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59489
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93266
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE156792
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111183
Abbreviations
- ACE and ACE2
- Human angiotensin-converting enzymes 1 and 2, respectively
- ADAM17
- A disintegrin and metallopeptidase domain 17 protein
- CCC
- Canadian Consensus Criteria
- 1994 CDC/Fukuda
- 1994 Centers for Diseases Control and Prevention Criteria
- COVID-19
- Coronavirus disease 2019
- DPP4
- Dipeptidyl peptidase-4
- EWAS
- epigenome-wide association study or (studies)
- GEO
- Gene Expression Omnibus
- GES
- gene expression study (or studies)
- GWAS
- Genome-wide association study (or studies)
- ME/CFS
- Myalgic encephalomyelitis/Chronic Fatigue Syndrome
- MERS
- middle east respiratory syndrome
- NCBI
- National Centre for Biotechnology Information
- PBMC
- peripheral blood mononuclear cell
- S1
- viral spike glycoprotein
- SARS-CoV-1
- severe acute respiratory syndrome coronavirus-1
- SARS-CoV-1/-2
- severe acute respiratory syndrome coronavirus-1/-2
- SNP
- single nucleotide polymorphism
- TMPRSS2
- transmembrane protease serine 2
- TSS
- transcription start site
